Company news

Phathom Pharmaceuticals, Inc. news in 2026

Phathom Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Phathom Pharmaceuticals to Participate in November Investor Conferences

November 4, 2026

Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx

November 3, 2026

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

October 29, 2026

Phathom Pharmaceuticals Provides Update on FDA Litigation

October 26, 2026

Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026

October 19, 2026

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

October 12, 2026

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

October 8, 2026

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

September 29, 2026

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

July 20, 2026

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

June 23, 2026

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

May 20, 2026

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

May 1, 2026

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

April 30, 2026

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

April 20, 2026

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

February 25, 2026

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

February 17, 2026

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

February 4, 2026

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

January 7, 2026

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 7, 2026

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

January 7, 2026

Shaya Prager Announces Opal Holdings Leasing Activity of 250,000 Square Feet Across Portfolio in 2025

January 6, 2026

Calls in 2026

Decks in 2026